Panacea Biotec Limited has informed the Exchange regarding Board meeting held on August 14, 2025.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Panacea Biotec reported strong top-line growth in Q1 FY26, with standalone revenue from operations nearly doubling to ₹11,225 lakh from ₹5,688 lakh a year ago, and consolidated revenue rising about 44% to ₹16,670 lakh. Despite higher raw material costs, the standalone net loss narrowed sharply to ₹670 lakh from ₹1,378 lakh, while the consolidated business swung to a net profit of ₹396 lakh from a loss of ₹1,588 lakh, helped by an exceptional income of ₹1,132 lakh. This exceptional item includes ₹858 lakh from a settlement with Apotex Inc. and ₹274 lakh from deferred consideration on earlier brand sales. The 41st AGM is scheduled for September 30, 2025, with the shareholder book closure period from September 26 to September 30, 2025. The auditor Suresh Surana & Associates LLP gave an unmodified limited review conclusion, though Note 4 flags that management has prepared accounts on a going concern basis given the company's history of losses.
The sharp revenue jump and swing to consolidated profit, supported by one-time settlement income, are positive signals, but standalone operations remain in the red and the explicit going-concern reference is a caution. The stock may react positively to the strong growth narrative, though investors should watch whether the vaccine order pipeline and cost controls translate into sustained profitability beyond the one-offs.